

CEBPA Mutation by PCR

Order Name: CEBPA PCR
Test Number: 9616990
Revision Date: 01/24/2025

TEST NAME		METHODOLOGY		LOINC CODE
CEBPA Mutation by PCR		Polymerase Chain Reaction		
SPECIMEN REQUIRE	MENTS			
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	5 mL (3 mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature
Alternate 1	5 mL (3 mL)	Whole Blood	Sodium Heparin (Green Top / No-Gel)	Room Temperature
Alternate 2	2 mL (1 mL)	Bone Marrow	EDTA (Lavender Top)	Room Temperature
Alternate 3	2mL (1mL)	Bone Marrow	Sodium Heparin (Green Top / No-Gel)	Room Temperature
Instructions	Specimen: 5mL(3mL) Whole Blood or 2mL (1mL) Bone Marrow Container: Lavender-top (EDTA) tube, green-top (sodium heparin) tube Collection: Indicate date and time of collection on the test request form. Submit specimen at room temperature ASAP, Keep at room temperature! (DO NOT FREEZE). Frozen samples will be rejected. Storage Instructions: Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C. Cause for Rejection: Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material.			

GENERAL INFORMATION	
Testing Schedule	Mon- Fri
Expected TAT	12-14 Days from set up.
Clinical Use	Determine prognosis in cytogenetically normal acute myelogenous leukemia (CN-AML The CEBPA (CCAAT/enhancer binding protein) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.
CPT Code(s)	81218
Service Provided By	labcorp Oklahoma, Inc.